STOCK TITAN

Elevation Oncology, Inc. - $ELEV STOCK NEWS

Welcome to our dedicated page for Elevation Oncology news (Ticker: $ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncology stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elevation Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elevation Oncology's position in the market.

Rhea-AI Summary
Elevation Oncology, Inc. (ELEV) CEO to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
conferences
-
Rhea-AI Summary
Elevation Oncology has announced financial results for Q3 2023, with cash totaling $94.8 million. They have initiated patient enrollment in the Phase 1 clinical trial for EO-3021, a potential anti-Claudin 18.2 ADC therapy. Preliminary safety and anti-tumor activity data are expected in 1H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Elevation Oncology CEO to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences
Rhea-AI Summary
Elevation Oncology announces dosing of first patient in Phase 1 clinical trial for EO-3021, a potential treatment for solid tumors expressing Claudin 18.2
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
-
Rhea-AI Summary
Elevation Oncology announces promising clinical data for EO-3021 in resistant gastric cancer. Closed public offering generates $46.5 million. Phase 1 trial in the US to begin in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
management
Rhea-AI Summary
Elevation Oncology has announced the pricing of its underwritten public offering, with a combined offering price of $2.2500 per share of common stock and accompanying warrant. The company expects to receive approximately $50 million in total gross proceeds. The offering is set to close on June 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.27%
Tags
-
Rhea-AI Summary
Elevation Oncology announces proposed underwritten public offering to fund clinical development of its lead product candidate EO-3021 and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.27%
Tags
-
Rhea-AI Summary
Elevation Oncology and CSPC Pharmaceutical announce promising initial clinical data for SYSA1801 (EO-3021) from Phase 1 study in China. EO-3021 shows a 47.1% objective response rate in patients with resistant/refractory gastric cancer expressing Claudin 18.2. Phase 1 clinical trial in the US planned for the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Elevation Oncology announces financial results for Q1 2023 and highlights recent business achievements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
Elevation Oncology, Inc.

Nasdaq:ELEV

ELEV Rankings

ELEV Stock Data

203.80M
19.16M
1.97%
86.3%
10.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About ELEV

elevation oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. we make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. our lead candidate, seribantumab, inhibits tumor growth driven by nrg1 fusions and is currently being clinically tested in the phase 2 crestone study for patients with tumors of any origin that have an nrg1 fusion. learn more about crestone at www.nrg1fusion.com. elevation oncology is backed by aisling capital, vertex ventures hc, qiming venture partners usa, driehaus capital management, and bvf partners.